Baxter launches PrisMax in U.S. for critically ill patients

“We looked at every detail during the PrisMax design process. Our team reviewed every piece of feedback from nephrologists, nurses and intensive care specialists, and then designed a system that can help simplify therapy administration and maximize efficiency,” said Gavin Campbell, General Manager of Baxter’s U.S. renal business. “We put our 20 years of expertise in CRRT and blood filtering technology to work to design an advanced system that allows for clinicians to customize treatment parameters to meet the needs of their patients.”

Building on Baxter’s Prismaflex technology, currently used by hospitals in more than 90 countries, the PrisMax system is used to treat patients with acute kidney injury (AKI) and select autoimmune diseases.

PrisMax includes new digital health features that allow hospitals to connect the system to electronic medical record (EMR) platforms. This enables straightforward integration of information from PrisMax to the EMR, allowing ICU nurses to spend less time manually documenting treatment data, while reducing the risk of transcription errors. PrisMax also features TrueVue Analytics, Baxter’s proprietary data and analytics platform. Hospitals can use TrueVue Analytics tools to evaluate data aggregated at the hospital level and assess the quality and effectiveness of their CRRT programs.

The TherMax blood warmer, which is used exclusively with the PrisMax system, is an important component for extracorporeal CRRT to warm the blood prior to returning to the body, helping keep the patient’s body temperature at a normal level.